secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bone Biologics Corp (BBLG)
CIK:        0001419554
Form:       8-K
Filed at:   2025-09-04T23:59:59+00:00
Accession:  0001493152-25-012604
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bone Biologics CEO updates on NB1 trial enrollment, shelf life extension, and $5M offering
--------------------------------------------------------------------------------

- Clinical trial enrollment slower than anticipated; expects to complete enrollment by year-end 2025.
- Achieved 18-month shelf life for NB1 protein, up from 12 months; plan to extend to 24 months.
- Filed U.S. patent application in June 2025 for proprietary rhNELL-1 compositions for bone conditions.
- Raised $5M gross in June public offering; expects cash to fund operations into Q2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419554/000149315225012604/0001493152-25-012604-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419554/000149315225012604/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-012604

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer